Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click on 'Find out more' to see our Cookie statement.

A major new initiative brings together top scientists in the UK, China and Saudi Arabia to transform CO2 into super-clean fuel and other commodities.

Professor Jinghai Li, recently appointed Director of the National Natural Science Foundation of China, is working with Professor Peter Edwards, Dr Tiancun Xiao and colleagues at Oxford and Cambridge and Prof Hamid Almegren of the King Abdulaziz City for Science and Technology in Saudi Arabia on an international and interdisciplinary project that opens up new and exciting possibilities for direct utilisation of CO2 at large-scale sources of fossil fuel combustion.  

China is the world’s largest CO2 emitter, and Saudi Arabia the world’s largest oil producer.  Despite major improvements in renewable energy technologies, the world still relies on hydrocarbon fossil fuels.  Fossil fuel combustion in power plants and petrochemical industries is responsible for the greatest amount of anthropogenic emissions of CO2, one of the most potent greenhouse gases and a major cause of climate change.  Mitigating the impact of CO2 with carbon capture and storage (CCS) brings its own challenges and is highly energy-intensive. 

The unique technology developed in the King Abdulaziz City for Science and Technology-Oxford Centre of Excellence in Petrochemicals uses a process called Flue Gas Reforming.  Flue gases are converted to synthesis gas (syngas) that is perfectly suited for the production of a wide range of fuels and industrially important chemicals.  This is achieved with new-generation, step-change catalysts that are designed to have minimal effect on a power plant’s generation capacity but are sufficiently robust to convert syngas into super-clean fuel or chemicals without the need for CCS.  The next challenge is to ensure that the resulting energy/CO2 balance of the entire process is carbon-neutral or ideally, carbon-negative.  This international, multidisciplinary approach represents a timely response to the historic achievements of the 2015 Paris Agreement.

 

Similar stories

£100 million donation from Ineos to create new institute to fight antimicrobial resistance

Chemistry Funding Medical science Zoology

Ineos, one of the world’s largest manufacturing companies, and the University of Oxford are launching a new world-leading institute to combat the growing global issue of antimicrobial resistance (AMR), which currently causes an estimated 1.5 million excess deaths each year.

Eight Oxford researchers, including five from MPLS, awarded major European Research Council funding

Chemistry Engineering Funding Plant sciences Zoology

European Research Council grants worth more than €16.3 million have been awarded to University of Oxford researchers for a range of cutting-edge projects.

$10 million gift for new Nanoscience Institute in Oxford

Biomedical engineering Chemistry Engineering Funding Materials science Medical science Physics

A new institute for nanoscience research is to open in Oxford thanks to a $10 million gift from The Kavli Foundation.

Top numbers of Oxford researchers make Highly Cited Researchers list

MPLS Research

Oxford University is delighted that 52 of its academics have been named on the annual Highly Cited Researchers™ 2020 list from Clarivate. This is the highest number of any institution in the UK and 2nd highest in Europe.

Institute of Physics awards for MPLS researchers

Award Chemistry Physics

Three MPLS academics and researchers have been awarded 2020 IOP Medals for their contributions to Physics - two in the Department of Physics and one in the Department of Chemistry.

Major Chemistry Sponsor forms New Public/Private Partnership to help manufacture and distribute Oxford Covid-19 Vaccine

Business and Industry COVID-19 Chemistry

Leading lights at Oxford University paved the way towards Oxford’s goal of global, rapid and equitable access to a safe, effective COVID-19 vaccine by facilitating an innovative public-private agreement for the manufacture and distribution of Oxford’s vaccine, ChAdOx1 nCoV-19.

Similar stories

£100 million donation from Ineos to create new institute to fight antimicrobial resistance

Chemistry Funding Medical science Zoology

Ineos, one of the world’s largest manufacturing companies, and the University of Oxford are launching a new world-leading institute to combat the growing global issue of antimicrobial resistance (AMR), which currently causes an estimated 1.5 million excess deaths each year.

Eight Oxford researchers, including five from MPLS, awarded major European Research Council funding

Chemistry Engineering Funding Plant sciences Zoology

European Research Council grants worth more than €16.3 million have been awarded to University of Oxford researchers for a range of cutting-edge projects.

$10 million gift for new Nanoscience Institute in Oxford

Biomedical engineering Chemistry Engineering Funding Materials science Medical science Physics

A new institute for nanoscience research is to open in Oxford thanks to a $10 million gift from The Kavli Foundation.

Top numbers of Oxford researchers make Highly Cited Researchers list

MPLS Research

Oxford University is delighted that 52 of its academics have been named on the annual Highly Cited Researchers™ 2020 list from Clarivate. This is the highest number of any institution in the UK and 2nd highest in Europe.

Institute of Physics awards for MPLS researchers

Award Chemistry Physics

Three MPLS academics and researchers have been awarded 2020 IOP Medals for their contributions to Physics - two in the Department of Physics and one in the Department of Chemistry.

Major Chemistry Sponsor forms New Public/Private Partnership to help manufacture and distribute Oxford Covid-19 Vaccine

Business and Industry COVID-19 Chemistry

Leading lights at Oxford University paved the way towards Oxford’s goal of global, rapid and equitable access to a safe, effective COVID-19 vaccine by facilitating an innovative public-private agreement for the manufacture and distribution of Oxford’s vaccine, ChAdOx1 nCoV-19.